Aims & Scope

Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.

The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. 

Cancer Biotherapy and Radiopharmaceuticals coverage includes:

  • Antibody drug conjugates
  • Fusion toxins and immunotoxins
  • Nanoparticle therapy
  • Vascular therapy
  • Inhibitors of proliferation signaling pathways

Cancer Biotherapy and Radiopharmaceuticals is under the editorial leadership of Editor-in-Chief Martin W. Brechbiel, PhD and other leading investigators. View the entire editorial board.

Audience: Oncologists, nuclear medicine researchers, radiologists, cancer researchers, pathologists, and epidemiologists, among others.

Indexed/Abstracted in:



PubMed Central;

Current Contents®/Life Sciences;

Current Contents®/Clinical Medicine;

Science Citation Index Expanded;

Science Citation Index®;

Biological Abstracts;

BIOSIS Previews;

Journal Citation Reports/Science Edition;

Prous Science Integrity®;

Derwent Drug File;

EMBASE/Excerpta Medica;



ProQuest databases;

CAB Abstracts;

Global Health;

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Upcoming Events

Apr 14 - Apr 18, 2018
Apr 30 - May 04, 2018